Conditions We're Supporting
This clinical study focuses on understanding and treating three conditions that can lead to serious kidney disease. Each of these conditions involves the immune system acting in ways that can harm the kidneys over time. Here’s a closer look at each one:
IgA Nephropathy (IgAN)
A rare autoimmune condition where the immune system produces antibodies, which accumulate in the kidneys, that leads to kidney inflammation.
Lupus Nephritis (LN)
A rare autoimmune condition where the immune system attacks the body's own cells, affecting many organs, including the kidneys.
C3 Glomerulopathy (C3G)
A rare autoimmune condition in which C3, a protein your body creates for protection, abnormally deposits in the kidneys, leading to kidney damage and affecting the kidney’s ability to filter blood.
What Happens Over Time
If left untreated, IgAN, LN, or C3G, may progress to kidney failure, necessitating kidney replacement therapy and life-long treatments.
To learn more about how ADX-097 may lessen kidney function loss, click "How Is The Study Drug Designed to Work?"
To learn more about how ADX-097 may lessen kidney function loss, click "How Is The Study Drug Designed to Work?"
HOW IS THE STUDY DRUG DESIGNED TO WORK?
The study drug is called ADX-097 and remains experimental.
It is designed to work by homing specifically to the inflamed tissue to inhibit the part of the immune system called the complement system.
Through a part of the molecule called factor H, it is designed to affect the part of the complement system called the alternative pathway (AP), which is important for amplifying the activation of the complement system. The complement system, and particularly the AP, is commonly overly activated in kidney diseases including Lupus Nephritis, IgA Nephropathy and C3 Glomerulopathy.
ADX-097 aims to inhibit the complement system to reduce the activity of the AP which may lessen kidney damage and kidney function loss, while also reducing the risk of side effects of common kidney disease-related medications and the need for frequent, high-dose treatments.
It is designed to work by homing specifically to the inflamed tissue to inhibit the part of the immune system called the complement system.
Through a part of the molecule called factor H, it is designed to affect the part of the complement system called the alternative pathway (AP), which is important for amplifying the activation of the complement system. The complement system, and particularly the AP, is commonly overly activated in kidney diseases including Lupus Nephritis, IgA Nephropathy and C3 Glomerulopathy.
ADX-097 aims to inhibit the complement system to reduce the activity of the AP which may lessen kidney damage and kidney function loss, while also reducing the risk of side effects of common kidney disease-related medications and the need for frequent, high-dose treatments.
